Legend Biotech Corp Net Income
| LEGN Stock | USD 17.59 0.01 0.06% |
As of the 16th of February 2026, Legend Biotech secures the Risk Adjusted Performance of (0.19), standard deviation of 3.34, and Mean Deviation of 2.48. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Legend Biotech Corp, as well as the relationship between them.
Legend Biotech Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9311 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -401.7 M | -381.6 M | |
| Net Loss | -142.3 M | -149.4 M | |
| Net Loss | -159.3 M | -167.3 M | |
| Net Loss | (2.23) | (2.34) | |
| Net Income Per E B T | 1.01 | 0.82 |
Legend | Net Income | Build AI portfolio with Legend Stock |
Evaluating Legend Biotech's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Legend Biotech Corp's fundamental strength.
Latest Legend Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Legend Biotech Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Legend Biotech Corp financial statement analysis. It represents the amount of money remaining after all of Legend Biotech Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Legend Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Legend Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (158.13 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Legend Net Income Regression Statistics
| Arithmetic Mean | (127,508,881) | |
| Coefficient Of Variation | (141.52) | |
| Mean Deviation | 146,545,271 | |
| Median | (2,784,000) | |
| Standard Deviation | 180,449,223 | |
| Sample Variance | 32561.9T | |
| Range | 527.6M | |
| R-Value | (0.69) | |
| Mean Square Error | 18148.1T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (24,692,707) | |
| Total Sum of Squares | 520990.8T |
Legend Net Income History
Other Fundumenentals of Legend Biotech Corp
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Legend Biotech Net Income component correlations
Legend Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Legend Biotech is extremely important. It helps to project a fair market value of Legend Stock properly, considering its historical fundamentals such as Net Income. Since Legend Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Legend Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Legend Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.7 | Return On Assets | Return On Equity |
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Legend Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Legend Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Legend Biotech.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Legend Biotech on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Legend Biotech Corp or generate 0.0% return on investment in Legend Biotech over 90 days. Legend Biotech is related to or competes with Disc Medicine, Zai Lab, Ascentage Pharma, Tarsus Pharmaceuticals, Adaptive Biotechnologies, Scholar Rock, and Celcuity LLC. Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discove... More
Legend Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Legend Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Legend Biotech Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 19.65 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 3.97 |
Legend Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Legend Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Legend Biotech's standard deviation. In reality, there are many statistical measures that can use Legend Biotech historical prices to predict the future Legend Biotech's volatility.| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.09) | |||
| Treynor Ratio | (6.66) |
Legend Biotech February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (6.65) | |||
| Mean Deviation | 2.48 | |||
| Coefficient Of Variation | (402.95) | |||
| Standard Deviation | 3.34 | |||
| Variance | 11.14 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.09) | |||
| Treynor Ratio | (6.66) | |||
| Maximum Drawdown | 19.65 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 3.97 | |||
| Skewness | (0.27) | |||
| Kurtosis | 1.31 |
Legend Biotech Corp Backtested Returns
Legend Biotech Corp has Sharpe Ratio of -0.22, which conveys that the firm had a -0.22 % return per unit of risk over the last 3 months. Legend Biotech exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Legend Biotech's Standard Deviation of 3.34, risk adjusted performance of (0.19), and Mean Deviation of 2.48 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Legend Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Legend Biotech is expected to be smaller as well. At this point, Legend Biotech Corp has a negative expected return of -0.77%. Please make sure to verify Legend Biotech's skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Legend Biotech Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.90 |
Excellent predictability
Legend Biotech Corp has excellent predictability. Overlapping area represents the amount of predictability between Legend Biotech time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Legend Biotech Corp price movement. The serial correlation of 0.9 indicates that approximately 90.0% of current Legend Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.9 | |
| Spearman Rank Test | 0.81 | |
| Residual Average | 0.0 | |
| Price Variance | 5.91 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Legend Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Legend Biotech Corp reported net income of (158.13 Million). This is 146.33% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 127.7% higher than that of the company.
Legend Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Legend Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Legend Biotech could also be used in its relative valuation, which is a method of valuing Legend Biotech by comparing valuation metrics of similar companies.Legend Biotech is currently under evaluation in net income category among its peers.
Legend Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Legend Biotech from analyzing Legend Biotech's financial statements. These drivers represent accounts that assess Legend Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Legend Biotech's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.3B | 4.0B | 5.3B | 3.0B | 2.7B | 2.5B | |
| Enterprise Value | 2.7B | 3.5B | 4.3B | 3.0B | 2.7B | 2.2B |
Legend Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Legend Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Legend Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Legend Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Legend Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Legend Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Legend Biotech's value.| Shares | State Street Corp | 2025-06-30 | 1.1 M | Capital Research & Mgmt Co - Division 3 | 2025-06-30 | 1.1 M | Federated Hermes Inc | 2025-06-30 | 1.1 M | Ubs Group Ag | 2025-06-30 | 1 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2025-06-30 | 983.5 K | Balyasny Asset Management Llc | 2025-06-30 | 947.6 K | Goldman Sachs Group Inc | 2025-06-30 | 941.9 K | Ivyrock Asset Management (hk) Ltd | 2025-06-30 | 869.9 K | Tang Capital Management Llc | 2025-06-30 | 830 K | Fmr Inc | 2025-06-30 | 25.7 M | Westfield Capital Management Company, L.p. | 2025-06-30 | 6.5 M |
Legend Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0692 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 2.66 B | ||||
| Shares Outstanding | 184.69 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 49.74 % | ||||
| Number Of Shares Shorted | 21.42 M | ||||
| Price To Book | 3.21 X | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 627.24 M | ||||
| Gross Profit | 132.68 M | ||||
| EBITDA | (113.16 M) | ||||
| Net Income | (158.13 M) | ||||
| Cash And Equivalents | 791.26 M | ||||
| Cash Per Share | 5.11 X | ||||
| Total Debt | 350.6 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 3.83 X | ||||
| Book Value Per Share | 5.47 X | ||||
| Cash Flow From Operations | (144.03 M) | ||||
| Short Ratio | 7.25 X | ||||
| Earnings Per Share | (1.28) X | ||||
| Target Price | 60.6 | ||||
| Number Of Employees | 2.9 K | ||||
| Beta | 0.091 | ||||
| Market Capitalization | 3.25 B | ||||
| Total Asset | 1.67 B | ||||
| Retained Earnings | (1.66 B) | ||||
| Working Capital | 1.01 B | ||||
| Net Asset | 1.67 B |
About Legend Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Legend Biotech Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Legend Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Legend Biotech Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Legend Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Legend Stock
Moving against Legend Stock
| 0.84 | DRTS | Alpha Tau Medical | PairCorr |
| 0.8 | EQ | Equillium | PairCorr |
| 0.8 | DSGN | Design Therapeutics | PairCorr |
| 0.77 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.67 | DNTH | Dianthus Therapeutics | PairCorr |
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.7 | Return On Assets | Return On Equity |
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.